Viaskin Peanut, the revolutionary “Peanut Patch,” just announced that the FDA has accepted their BLA. The BLA is their Biologics License Application, which is an important element in getting FDA approval.
DBV Technologies, the French company developing the peanut patch, has been on a roller coaster over the last few years. In total, Viaskin Peanut has performed 8 clinical trials on human subjects, involving over 1,000 patients and their families. Patient interest continues to grow, which means increased media visibility. That also means that they’ve received uncomfortable bad press during routine scientific setbacks.
The road to FDA approval is long, and it’s normal for treatments to encounter problems along the way. Failure is part of the scientific process and is always a learning experience.